Univariate analysis showed that the PFS of advanced NSCLC patients with EGFR exon 18 mutations was significantly associated with molecular subtype (P < 0.001) and treatment pattern (P = 0.023) (Table 4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.